Jun 17, 2020
Kangpu to Present Two Posters at the 2020 American Association for Cancer Research (AACR) Annual Meeting
Jun 15, 2020
Global Prostate Cancer Market Analysis to 2028 - Prostate Cancer Market Expected to Increase Despite Generic Abiraterone Entry
Jun 09, 2020
Cardiff Oncology Announces Expanded Access Program for Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer as Follow-On to Fast Track Designation
May 28, 2020
Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer
May 19, 2020
Cardiff Oncology Announces Private Placement Investment by Board of Directors and Chief Executive Officer
Apr 08, 2020
Trovagene to Present at the 19th Annual Needham Healthcare Conference
Mar 09, 2020
The global prostate cancer treatment market was valued at $6,887 million in 2018, and is projected to reach $9,904 million by 2026, registering a CAGR of 4.6% from 2019 to 2026
Feb 27, 2020
Trovagene Announces Fourth Quarter and Full-Year 2019 Results
Feb 13, 2020
Trovagene Presents Phase 2 Data Demonstrating the Ability of Onvansertib to Overcome Zytiga®-Resistance and Provide Clinical Benefit for mCRPC Patients
Feb 03, 2020
Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU
Nov 14, 2019
Trovagene Presents Positive Data in Metastatic Prostate Cancer Phase 2 Trial Showing Clinical Response in Patients Resistant to Zytiga®
Oct 03, 2019
Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Niraparib for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Aug 15, 2019
Trovagene to Present New Data from Onvansertib Phase 2 Study in Metastatic Castration-Resistant Prostate Cancer at Asia-Pacific Prostate Cancer Conference
Apr 02, 2019
Early Data from Phase 2 Trial Indicates Activity of Onvansertib in Prostate Cancer Patients Showing Initial Resistance to Anti-Androgen Therapy
Feb 14, 2019
Trovagene Presents Update on Phase 2 Study of Onvansertib in Combination with Zytiga in Patients with mCRPC at ASCO-GU Conference
Feb 14, 2019
Janssen Announces Preliminary Results from Phase 2 GALAHAD Study in Adults with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Pathway Defects (DRD)
Feb 05, 2019
Bayer to Showcase New Data from its Growing Cancer Portfolio at 2019 ASCO GU Cancers Symposium
Jan 23, 2019
Trovagene Announces New Patent Issued for Combination of Onvansertib with Anti-Androgen Drugs to Treat Non-Metastatic and Metastatic Prostate Cancer
Jan 14, 2019
Leap Therapeutics Announces an Investigator-Initiated Study of DKN-01 in Patients with DKK1+ Advanced Prostate Cancer
Oct 26, 2018
Court Issues Ruling in ZYTIGA® Patent Infringement Litigation